Feng Li1, Haibo Hu2, Shuo Gu3, Xin Chen4, Qing Sun3. 1. Department of Anesthesiology, The First People's Hospital of Yancheng Yancheng 224006, Jiangsu Province, China. 2. Department of Cardiothoracic Surgery, The Affiliated Huai'an Hospital of Xuzhou Medical College Huai'an 223002, Jiangsu Province, China. 3. Department of Urology, Huai'an First People's Hospital, Nanjing Medical University Huai'an 223300, Jiangsu Province, China. 4. Department of Anesthesiology, Huai'an First People's Hospital, Nanjing Medical University Huai'an 223300, Jiangsu Province, China.
Abstract
OBJECTIVE: To compare the platelet to lymphocyte ratio (PLR) in normal people, benign prostatic hyperplasia (BPH) patients and prostate cancer (PCA) patients, and to explore the prognostic role of PLR in PCA. METHODS: 155 normal people, 168 BPH patients and 103 PCA patients were enrolled. PCA patients were divided into PLR low value group (PLR<150) and PLR high value group (PLR≥150), and the difference of patients' clinical characteristics between high value group and low value group was comparative studied. RESULTS: The differences of PLR among normal people, BPH patients and PCA patients were statistically significant. In addition, platelet counts, neutrophil counts, PSA level, LDH level, AKP level, CRP level and alkaline phosphatase level were also significantly increased in PLR high value group, while the hemoglobin level was decreased. Besides, serious events such as coma during hospitalization were also more likely to appear in PLR high value group. PCA patients had an average follow-up of 3 years, and a total of 25 cases of patients died, including 11 (16.4%) cases in the PLR low value group, and 14 (38.9%) cases in PLR high value group with. Three years survival rate of patients in high value group was significantly reduced. Additionally, PLR was a possible risk factor associated with mortality, and an independent predictor of all-cause mortality during follow-up. CONCLUSION: PLR is significantly increased in PCA patients, and it is an independent predictor of 3-year mortality in PCA patients.
OBJECTIVE: To compare the platelet to lymphocyte ratio (PLR) in normal people, benign prostatic hyperplasia (BPH) patients and prostate cancer (PCA) patients, and to explore the prognostic role of PLR in PCA. METHODS: 155 normal people, 168 BPH patients and 103 PCApatients were enrolled. PCApatients were divided into PLR low value group (PLR<150) and PLR high value group (PLR≥150), and the difference of patients' clinical characteristics between high value group and low value group was comparative studied. RESULTS: The differences of PLR among normal people, BPH patients and PCApatients were statistically significant. In addition, platelet counts, neutrophil counts, PSA level, LDH level, AKP level, CRP level and alkaline phosphatase level were also significantly increased in PLR high value group, while the hemoglobin level was decreased. Besides, serious events such as coma during hospitalization were also more likely to appear in PLR high value group. PCApatients had an average follow-up of 3 years, and a total of 25 cases of patients died, including 11 (16.4%) cases in the PLR low value group, and 14 (38.9%) cases in PLR high value group with. Three years survival rate of patients in high value group was significantly reduced. Additionally, PLR was a possible risk factor associated with mortality, and an independent predictor of all-cause mortality during follow-up. CONCLUSION: PLR is significantly increased in PCApatients, and it is an independent predictor of 3-year mortality in PCApatients.
Entities:
Keywords:
Platelet to lymphocyte ratio; clinical significance; mortality; prognosis; prostate cancer
Authors: Kyriakos Neofytou; Elizabeth C Smyth; Alexandros Giakoustidis; Aamir Z Khan; David Cunningham; Satvinder Mudan Journal: Med Oncol Date: 2014-09-14 Impact factor: 3.064
Authors: Arnoud J Templeton; Olga Ace; Mairéad G McNamara; Mustafa Al-Mubarak; Francisco E Vera-Badillo; Thomas Hermanns; Boštjan Seruga; Alberto Ocaña; Ian F Tannock; Eitan Amir Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-05-03 Impact factor: 4.254
Authors: D Andrew Loblaw; Katherine S Virgo; Robert Nam; Mark R Somerfield; Edgar Ben-Josef; David S Mendelson; Richard Middleton; Stewart A Sharp; Thomas J Smith; James Talcott; Maryellen Taplin; Nicholas J Vogelzang; James L Wade; Charles L Bennett; Howard I Scher Journal: J Clin Oncol Date: 2007-04-02 Impact factor: 44.544
Authors: Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke Journal: Clin Cancer Res Date: 2010-10-18 Impact factor: 12.531
Authors: Guru Sonpavde; Gregory R Pond; Andrew J Armstrong; Stephen J Clarke; Janette L Vardy; Arnoud J Templeton; Shaw-Ling Wang; Jolanda Paolini; Isan Chen; Edna Chow-Maneval; Mariajose Lechuga; Matthew R Smith; M Dror Michaelson Journal: Clin Genitourin Cancer Date: 2014-03-15 Impact factor: 2.872
Authors: Kultigin Turkmen; Fatih Mehmet Erdur; Fatih Ozcicek; Adalet Ozcicek; Emin Murat Akbas; Aysu Ozbicer; Levent Demirtas; Suleyman Turk; H Zeki Tonbul Journal: Hemodial Int Date: 2013-03-24 Impact factor: 1.812
Authors: M A Eisenberger; B A Blumenstein; E D Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; I M Thompson; A J Bueschen; B A Lowe Journal: N Engl J Med Date: 1998-10-08 Impact factor: 91.245
Authors: Betina Katz; Sabrina T Reis; Nayara I Viana; Denis R Morais; Caio M Moura; Nelson Dip; Iran A Silva; Alexandre Iscaife; Miguel Srougi; Katia R M Leite Journal: PLoS One Date: 2014-11-19 Impact factor: 3.240
Authors: Igor Tsaur; Anika Noack; Jasmina Makarevic; Elsie Oppermann; Ana Maria Waaga-Gasser; Martin Gasser; Hendrik Borgmann; Tanja Huesch; Kilian M Gust; Michael Reiter; David Schilling; Georg Bartsch; Axel Haferkamp; Roman A Blaheta Journal: Cancer Res Treat Date: 2014-10-13 Impact factor: 4.679